Genmab — Maj 2017
-
Vedr. NCT 01077518 (OFA + Bendamustine) mod NHL unresponsive to Rituximab. Iflg. Clinical Trials var Primary Completion Date i April 2017 og studiet er "ongoiong, bud not recruiting". Dette er vist Complement A+B studiet. Kører dette stadig og hvornår kan der i så fald forventes nyt ??
-
det starter om lidt
-
-
Er vi gået i frit fald ?
-
Se hvem der køber og sælge og sepå omsætningen. Der er ikke noget bekymrende forløbig.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind
